- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01920698
Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR)
Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation.
The objective of this trial is to compare the safety, the efficacy and the cost-effectiveness of 2 therapeutic strategies (optimal standard of care therapy alone versus percutaneous MitraClip procedure and optimal standard of care therapy) in patients with severe secondary mitral regurgitation.
This trial is a French, multicenter and randomized trial. Patients enrolled will be clinically followed for 2 years (phone call at 1 month, clinical visit at 6 months, 12 months and 24 months).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- CHU d'Angers
-
Besancon, France
- CHU de Besancon
-
Bordeaux, France
- CHU de Bordeaux
-
Brest, France
- CHRU La Cavale Blanche
-
Bron, France
- Groupement Hospitalier Est
-
Caen, France, 14000
- CHU caen
-
Clermont Ferrand, France, 63000
- Hôpital Gabriel Montpied
-
Creteil, France
- APHP Hôpital Henri Mondor
-
Grenoble, France, 38700
- CHU de Grenoble
-
Le Chesnay, France, 78150
- Hôpital privé de Parly 2
-
Le Plessis Robinson, France
- Centre Chirurgical Marie Lannelongue
-
Lille, France
- CHU de Lille
-
Lille, France
- Hôpital Privé Le Bois
-
Marseille, France
- Hopital de la Timone
-
Marseille, France
- Hôpital privé Clairval
-
Marseille, France, 13285
- Hôpital Saint-Joseph
-
Massy, France
- Institut Hospitalier Jacques Cartier
-
Metz-Tessy, France, 74370
- Ch Annecy Genevois
-
Montpellier, France
- CHU de Montpellier
-
Montpellier, France
- Clinique du Millénaire
-
Nancy, France
- Chu de Nancy
-
Nantes, France
- CHU de Nantes
-
Neuilly Sur Seine, France, 92200
- Centre chirurgicale Ambroise Paré
-
Nice, France, 06001
- Hôpital Pasteur
-
Paris, France, 75015
- Hôpital Européen Georges Pompidou
-
Paris, France, 75014
- Institut Mutualiste Montsouris
-
Paris, France
- APHP Hôpital Bichat
-
Paris, France, 75013
- Groupe Hospitalier La Salpétrière
-
Poitiers, France
- CHRU La Milétrie
-
Rennes, France
- CHU de Rennes
-
Rouen, France
- CHU Rouen
-
Saint Denis, France
- Centre Cardiologique du Nord
-
Saint Laurent Du Var, France
- Institut Arnault Tzanck
-
Saint-Étienne, France, 42055
- Hopital Nord
-
Strasbourg, France
- CHU de Strasbourg
-
Toulouse, France, 31076
- Clinique PASTEUR
-
Toulouse, France
- CHU de Toulouse
-
Tours, France
- CHRU De Tours
-
Tours, France
- Clinique Cardiologique Saint Gatien
-
Villeurbanne, France
- Clinique du Tonkin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years old
- Severe secondary mitral regurgitation characterised, according to the European guidelines and recommendations, by a regurgitant volume>30 mL/beat or an effective regurgitant orifice>20 mm².
- New York heart Association Class≥ II.
- Left ventricular ejection fraction between 15% and 40%
- Minimum of 1 hospitalization for heart failure within 12 months preceding randomization
- Optimal standard of care therapy for heart failure according to investigator.
- Not eligible for a mitral surgery intervention according to the Heart Team.
- Willingness to participate in the study and signed written informed consent
- Affiliation to a health insurance system or a similar system
Exclusion Criteria:
- Eligible for a mitral surgery intervention according to the Heart Team.
- Primary mitral regurgitation.
- Myocardial infarction or coronary bypass grafting surgery within three months prior to randomization.
- Cardiac resynchronization therapy within three months prior to randomization.
- Cardioversion within three months prior to randomization
- Transcatheter aortic valve implantation within three months prior to randomization
- Need for any cardiovascular surgery (including registration on cardiac transplant list).
- Coronary angioplasty within one month prior to randomization.
- Previous surgical mitral valve repair.
- Renal replacement therapy.
- Active infection requiring current antibiotic therapy.
- Severe hepatic insufficiency.
- Stroke within three months prior to randomization.
- Concurrent medical condition with a life expectancy of less than 12 months.
- Uncontrolled arterial hypertension.
- Hypersensitivity to nitinol.
- Participation to another trial.
- Pregnancy.
- No affiliation to a health insurance system.
- Legal protection measure (guardianship or curatorship)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MitraClip Device
Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
|
MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
|
Other: Control
Patients randomized to the Control group will receive optimal therapy alone
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
All-cause mortality and unplanned hospitalizations for heart failure
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality, cardiac mortality
Time Frame: 30 days, 6 months, 12 months, and 24 months.
|
30 days, 6 months, 12 months, and 24 months.
|
|
Survival with no major cardiovascular events
Time Frame: 30 days, 6 months, 12 months, and 24 months.
|
30 days, 6 months, 12 months, and 24 months.
|
|
Serious Adverse Events
Time Frame: 30 days, 6 months, 12 months and 24 months.
|
Any serious adverse events cardiovascular or not occurring within each group.
|
30 days, 6 months, 12 months and 24 months.
|
Change in Quality of Life score as measured by the European Quality of Life-5 Dimensions instrument.
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
Change in functional evaluation
Time Frame: 12 months
|
12 months
|
|
Change in echocardiographic evaluation between baseline at 6, 12 and 24 months.
Time Frame: 6 months, 12 months and 24 months
|
6 months, 12 months and 24 months
|
|
Change in biomarkers (BNP levels, creatinine) at 6 months and 12 months
Time Frame: 6 months and 12 months
|
6 months and 12 months
|
|
Cost-effectiveness of each strategy at 12 months
Time Frame: 12 months
|
Cost-effectiveness of each therapeutic strategy will be assessed by the evaluation of medical costs linked to the pathology (hospitalizations, consultations, and external medical costs (biology, radiology, medications) and compared in the 2 groups during the first 12 months of follow up.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: JEAN FRANCOIS OBADIA, MD, Hospices Civils de Lyon
Publications and helpful links
General Publications
- Iung B, Messika-Zeitoun D, Boutitie F, Trochu JN, Armoiry X, Maucort-Boulch D, Obadia JF, Vahanian A. Characteristics and Outcome of COAPT-Eligible Patients in the MITRA-FR Trial. Circulation. 2020 Dec 22;142(25):2482-2484. doi: 10.1161/CIRCULATIONAHA.120.049743. Epub 2020 Dec 21. No abstract available.
- Messika-Zeitoun D, Iung B, Armoiry X, Trochu JN, Donal E, Habib G, Brochet E, Thibault H, Piriou N, Cormier B, Tribouilloy C, Guerin P, Lefevre T, Maucort-Boulch D, Vahanian A, Boutitie F, Obadia JF. Impact of Mitral Regurgitation Severity and Left Ventricular Remodeling on Outcome After MitraClip Implantation: Results From the Mitra-FR Trial. JACC Cardiovasc Imaging. 2021 Apr;14(4):742-752. doi: 10.1016/j.jcmg.2020.07.021. Epub 2020 Sep 16.
- Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, Lefevre T, Messika-Zeitoun D, Guerin P, Cormier B, Brochet E, Thibault H, Himbert D, Thivolet S, Leurent G, Bonnet G, Donal E, Piriou N, Piot C, Habib G, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Saint Etienne C, Leroux L, Gilard M, Samson G, Rioufol G, Maucort-Boulch D, Obadia JF; MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail. 2019 Dec;21(12):1619-1627. doi: 10.1002/ejhf.1616. Epub 2019 Nov 18.
- Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefevre T, Piot C, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N; MITRA-FR Investigators. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018 Dec 13;379(24):2297-2306. doi: 10.1056/NEJMoa1805374. Epub 2018 Aug 27.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013.798
- 2013-A00464-41 (Other Identifier: IDRCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on control
-
Claudia M. WittCompleted
-
University of California, San FranciscoWithdrawn
-
The George InstituteChanghai Hospital; University of CalgaryNot yet recruiting
-
Universidad Nacional de Educación a DistanciaMinisterio de Economía y Competitividad, SpainUnknownChronic Pain | FibromyalgiaSpain
-
University of California, Los AngelesThe National Council on Aging; City of Los Angeles Department of Aging; Los Angeles...Completed
-
Queen's University, BelfastPublic Health Agency, Health and Social Care Research and Development; Tiny...Completed
-
National Taiwan University HospitalEnrolling by invitationCognitive Function | Atrial Fibrillation, PersistentTaiwan
-
Takeshi MorimotoUniversity of the RyukyusActive, not recruitingCoronary Artery Disease | Hypertension | Type 2 Diabetes | DyslipidemiaJapan
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Vanderbilt University Medical CenterCompleted